Older people with idiopathic REM sleep behavior disorder, with constipation and reduced nigro-putaminal dopaminergic function, are at high risk of phenoconversion to overt synucleinopathy.
Why this matters
Neuroprotective treatments in the early stages of synucleinopathies are key to rescuing brain structure and function. However, their effectiveness in early disease can be hindered by the inability to identify those with prodromal neurodegenerative disease.
Dopamine transporter single photon emission tomography is a novel tool that could help to stratify participants in neuroprotective clinical trials and ultimately improve long-term treatment outcomes.